Cargando…

The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform

BACKGROUND: Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses to address the many outstan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maguire, Brittany J., Dahal, Prabin, Rashan, Sumayyah, Ngu, Roland, Boon, Anca, Forsyth, Colin, Strub-Wourgaft, Nathalie, Chatelain, Eric, Barreira, Fabiana, Sosa-Estani, Sergio, Guérin, Philippe J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428795/ https://www.ncbi.nlm.nih.gov/pubmed/34398888 http://dx.doi.org/10.1371/journal.pntd.0009697

Ejemplares similares

A new patient registry for Chagas disease
por: Hotez, Peter, et al.
Publicado: (2020)

Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis
por: Singh-Phulgenda, Sauman, et al.
Publicado: (2021)

Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
por: Guérin, Philippe J., et al.
Publicado: (2022)

The translational challenge in Chagas disease drug development
por: Kratz, Jadel M, et al.
Publicado: (2022)

Congenital Chagas disease: an update
por: Carlier, Yves, et al.
Publicado: (2015)

Therapy of Chagas Disease: Implications for Levels of Prevention
por: Sosa-Estani, Sergio, et al.
Publicado: (2012)

The Need of a Neonatal Preparation for Chagas Disease
por: Sosa-Estani, Sergio, et al.
Publicado: (2005)

Integrated control of Chagas disease for its elimination as public health problem - A Review
por: Sosa-Estani, Sergio, et al.
Publicado: (2015)

Antiparasitic treatment with itraconazole and amiodarone in 2 dogs with severe, symptomatic Chagas cardiomyopathy
por: Malcolm, Elizabeth L., et al.
Publicado: (2022)

A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease
por: Torrico, Faustino, et al.
Publicado: (2022)

Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis
por: Ciapponi, Agustín, et al.
Publicado: (2020)

Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans
por: Dahal, Prabin, et al.
Publicado: (2021)

Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform
por: Bush, Jacob T., et al.
Publicado: (2017)

Aplastic Anemia and Chagas Disease: T. cruzi Parasitemia Monitoring by Quantitative PCR and Preemptive Antiparasitic Therapy
por: Carvalho, Noêmia Barbosa, et al.
Publicado: (2022)

WHF IASC Roadmap on Chagas Disease
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

COVID-19: Implications for People with Chagas Disease
por: Zaidel, Ezequiel José, et al.
Publicado: (2020)

Critical analysis of Chagas disease treatment in different countries
por: Mendes, Fernanda de Souza Nogueira Sardinha, et al.
Publicado: (2022)

The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?
por: Guerin, Philippe J, et al.
Publicado: (2020)

Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women
por: Carlier, Yves, et al.
Publicado: (2011)

Trypanocide Treatment of Women Infected with Trypanosoma cruzi and Its Effect on Preventing Congenital Chagas
por: Fabbro, Diana L., et al.
Publicado: (2014)

The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America
por: Picado, Albert, et al.
Publicado: (2018)

Chagas Disease Drug Discovery in Latin America—A Mini Review of Antiparasitic Agents Explored Between 2010 and 2021
por: de Oliveira, Ramon G., et al.
Publicado: (2021)

Chagas disease research and development: Is there light at the end of the tunnel?
por: Chatelain, Eric
Publicado: (2016)

Guidelines should not pool evidence from uncomplicated and severe COVID-19
por: White, Nicholas J, et al.
Publicado: (2021)

WHO COVID-19 therapeutic guidelines – Authors' reply
por: White, Nicholas J, et al.
Publicado: (2021)

Cultural barriers to effective communication between Indigenous communities and health care providers in Northern Argentina: an anthropological contribution to Chagas disease prevention and control
por: Dell’Arciprete, Ana, et al.
Publicado: (2014)

Chagas disease control-surveillance in the Americas: the multinational initiatives and the practical impossibility of interrupting vector-borne Trypanosoma cruzi transmission
por: de Arias, Antonieta Rojas, et al.
Publicado: (2022)

Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases
por: Alvar, Jorge, et al.
Publicado: (2020)

Text message interventions for follow up of infants born to mothers positive for Chagas disease in Tucumán, Argentina: a feasibility study
por: Cormick, Gabriela, et al.
Publicado: (2015)

Baseline results of a living systematic review for COVID-19 clinical trial registrations
por: Maguire, Brittany J., et al.
Publicado: (2020)

Arylmethylamino steroids as antiparasitic agents
por: Krieg, Reimar, et al.
Publicado: (2017)

Nanoparticles for antiparasitic drug delivery
por: Sun, Yuzhu, et al.
Publicado: (2019)

Antifungal and Antiparasitic Drug Delivery
por: Torrado, Juan José, et al.
Publicado: (2020)

Antiparasitic agents produced by microorganisms
por: Shiomi, Kazuro, et al.
Publicado: (2004)

Can a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine protect against mpox?
por: Ogoina, Dimie, et al.
Publicado: (2023)

Translational challenges of animal models in Chagas disease drug development: a review
por: Chatelain, Eric, et al.
Publicado: (2015)

Human Trypanosoma cruzi chronic infection leads to individual level steady-state parasitemia: Implications for drug-trial optimization in Chagas disease
por: De Salazar, Pablo M., et al.
Publicado: (2022)

Prognostic prediction models for clinical outcomes in patients diagnosed with visceral leishmaniasis: protocol for a systematic review
por: Wilson, James, et al.
Publicado: (2023)

Gender disparity in cases enrolled in clinical trials of visceral leishmaniasis: A systematic review and meta-analysis
por: Dahal, Prabin, et al.
Publicado: (2021)

Antiparasitic Effects of Selected Isoflavones on Flatworms
por: Faixová, D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vb0div4pae0a5r34hj5liajasv